All the makings of a first-class blockbuster drug
Paradigm Biopharmaceuticals Limited (ASX:PAR) begins 2021 on the cusp of several pivotal Phase 3 clinical trials, with aspirations to successfully commercialise pentosan polysulfate sodium (PPS) for the treatment of the world’s third-largest unmet medical need, osteoarthritis (OA).
Via an exclusive supply agreement with bene pharmaChem GmBH, Paradigm has access to a semi-synthetically produced heparin-like macromolecular carbohydrate derivative (extracted from beech trees), that for decades ‘big pharma’ has failed to develop into a bio-equivalent molecule. Paradigm has accumulated compelling data that confirms PPS is effective in reducing pain, whilst improving function and mobility, and is well tolerated.
In addition, x-ray and MRI images provide evidence that PPS slows the advancement of OA, indicating disease modifying characteristics. This is significant, as current treatments and competing products in development have mono-specific applications, and in many cases have limited tolerability due to adverse effects.
Paradigm has a multi-model product, with several patents across many applications.
2021 is a year for anticipated partnerships, and/or commercial discussions for any one of the company’s applications. Paradigm is well-positioned to successfully commercialise Zilosul® (injectible PPS) as a first-class blockbuster drug.
Download the first full, in-depth report on Paradigm Biopharmaceuticals Ltd here.